BYBC-1 is a selective G4-RNA-targeting ligand with high affinity forKRAS and NRAS G4-RNAs (Kd = 0.05-0.28 µM). BYBC-1 stabilizes G4-RNA structures in KRAS and NRAS mRNA, blocks thePI3K/AKT and MAPK/ERK pathways, activates the DNA damage response (DDR), suppresses energy metabolism, and induces S-phase arrest and apoptosis. BYBC-1 exhibits high selectivity over non-malignant fibroblasts and significantly inhibits the growth of HCT-116 xenograft tumors in vivo. BYBC-1 can be used for the study of colorectal cancer[1].
